Streetbeat News

Analyst Ratings

TJX

Barclays analyst Adrienne Yih maintains an Overweight rating on TJX Companies and raises the price target from $95 to $101.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 11:00 am

ROST

Barclays analyst Adrienne Yih maintains an Overweight rating on Ross Stores (NASDAQ:ROST) and raises the price target from $122 to $129.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 10:59 am

PANW

Rosenblatt analyst Catharine Trebnick has reiterated a 'Buy' rating on Palo Alto Networks (NASDAQ:PANW) and maintained a price target of $250.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:59 am

NVTS

Rosenblatt analyst Kevin Cassidy maintains a 'Buy' rating on Navitas Semiconductor (NASDAQ:NVTS) and has raised the price target from $10 to $12.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:58 am

CMDXF

Barclays analyst David Anderson has maintained an Underweight rating on Computer Modelling Group (OTC:CMDXF) and raised the price target from C$6 to C$7.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 10:58 am

EDSA

HC Wainwright & Co. analyst Vernon Bernardino maintains a 'Buy' rating on Edesa Biotech (NASDAQ:EDSA) but lowers the price target from $16 to $10.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:57 am

RMTI

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Rockwell Medical (NASDAQ:RMTI) and maintained a price target of $11.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:56 am

MGIC

Barclays analyst Tavy Rosner maintains an Overweight rating on Magic Software (NASDAQ:MGIC) but lowers the price target from $23 to $18.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 10:56 am

INDP

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Indaptus Therapeutics (NASDAQ:INDP) and maintained a $12 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:55 am

COCP

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Cocrystal Pharma (NASDAQ:COCP) and maintained a $12 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:55 am